Luaran Klinik dan Biaya Terapi pada pasien COVID 19 di RSUD Dr Moewardi Surakarta

RINI BUDI ASTUTI, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS; Dr. apt. Ika Puspitasari, M.Si

2022 | Tesis | MAGISTER FARMASI KLINIK

Penanganan Corona Virus Disease 19 (COVID 19) membutuhkan intervensi yang beragam. Keparahan penyakit berpengaruh terhadap terapi obat dan biaya terapi. Penelitian ini bertujuan unuk mengetahui gambaran terapi obat, biaya terapi dan luaran klinik berupa LOS (length of stay) serta kematian pada pasien COVID 19. Penelitian ini merupakan penelitian deskriptif dengan rancangan cross sectional. Subjek dalam penelitian ini adalah pasien COVID 19 yang dilakukan Januari 2021 sampai Maret 2021. Data penelitian bersumber data sekunder data sekunder yakni catatan medis pasien dan rincian biaya. Analisis data dilakukan secara deskriptif meliputi gambaran dan biaya terapi serta luaran klinik pada pasien COVID 19 dengan ringan, berat dan kritis Hasil penelitian pada pasien COVID 19 dengan derajat ringan (63 pasien), berat (24 pasien) dan kritis (9 pasien) sebanyak 88,7 persen berusia antara 19 sampai 59 tahun dengan komorbid terbanyak adalah diabetes melitus (15,6 persen). Terapi yang diberikan yaitu antivirus (90,6 persen), antibiotik (94,8 persen), vitamin (98,9 persen), antikoagulan (57,3 persen) dan kortikosteroid (20,8 persen). Median (IQR) lama rawat inap pasien dengan derjat ringan, berat dan kritis masing - masing 8 (6 sampai 10), 10 (8 sampai 13,5) dan 8 (2,5 sampai 11,5) hari, sedangkan yang meninggal sebesar 1,6 persen, 41,7 persen dan 44,4 persen. median (IQR) biayta total pasien dengan derajat ringan, berat dan kritis masing masing sebesar Rp 14.655.105,00 (Rp 12.330.604,00 sampai Rp 23.308.424,00), Rp 31.831.913,00 9Rp 16.289.959,00 sampai Rp 63.668.182,75) dan Rp 13.785.385,00 (Rp 4.370.673,00 sampai Rp 11.731.132,00

Handling Corona Virus Disease 19 (COVID 19) requires various interventionts. The severity of the disease affects drug therapy and the cost of therapy. This study aims to determine description of drug therapy, cost if therapy and clinical outcomes in the form of LOS (length of stay) and mortality in COVID 19 patients. This research is a descriptive study with a cross sectional design. The subjects in this study were COVID 19 patients whi were hispitalized at the Dr Moewardi Surakarta in the period Jnauary 2021 to march 2021. The research data comes from secondary data, namely patient medical records and detail of costs. Data analysis was carried out descriptively including descriptions and cost of therapy and clinical outcomes for COVID 19 patients with mild, severe and critical degrees. The result of the study on COVID 19 patients with mild (63 patients), severe (24 patients), and critical (9 patients), as many as 88.7 percent agend between 18 to 59 years with the most comorbidities being diabetes mellitus (15.6 percent). The therapy given was antiviral (90.6 percent), antibiotics (94.8 percent), vitamins (98,9 percent), anticoagulant (57.3 percent0 and corticosteroids (20.8 percent). The median (IQR) length of stay of patients with mild , severe and critical degrees were 8 (6 to 10). 10 (8 to 13.5) and 8 (2.5 to 11.5) days. while those who died by 1,6 percent, 41.7 percent., and 44.4 percent. The median (IQR) total cost of patients with mild, severe and critical degrees respectively Rp 14,655,105.00 (Rp 12,330,604 to Rp 23,308,424.00), Rp 31,831,913.00 (Rp 16,289,859.00 to Rp 63,668,182.75) and Rp 13,785,385.00 (Rp 4,370,673.00 to Rp 11,731,132.00).

Kata Kunci : COVID 19, biaya, gambaran terapi, luaran klinik